References
- Sung H , FerlayJ , SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J. Clin.71(3), 209–249 (2021).
- Siegel RL , MillerKD , JemalA. Cancer statistics, 2020. Cancer J. Clin.70(1), 7–30 (2020).
- Davies L , MorrisLG , HaymartMet al. American association of clinical endocrinologists and american college of endocrinology disease state clinical review: the increasing incidence of thyroid cancer. Endocrine Pract.21(6), 686–696 (2015).
- Hundahl SA , FlemingID , FremgenAM , MenckHR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see commetns]. Cancer83(12), 2638–2648 (1998).
- Döbert N , MenzelC , OeschgerS , GrünwaldF. Differentiated thyroid carcinoma: the new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients. Thyroid14(1), 65–70 (2004).
- Francis GL , WaguespackSG , BauerAJet al. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid25(7), 716–759 (2015).
- Loh KC , GreenspanFS , GeeL , MillerTR , YeoPP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metabol.82(11), 3553–3562 (1997).
- Kitamura Y , ShimizuK , NagahamaMet al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J. Clin. Endocrinol. Metabol.84(11), 4043–4049 (1999).
- Lupi C , GianniniR , UgoliniCet al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metabol.92(11), 4085–4090 (2007).
- Trovisco V , SoaresP , PretoAet al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch.446(6), 589–595 (2005).
- Frasca F , NuceraC , PellegritiGet al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr. Relat. Cancer15(1), 191–205 (2008).
- Tang KT , LeeCH. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. JCMA73(3), 113–128 (2010).
- Kim TH , ParkYJ , LimJAet al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer118(7), 1764–1773 (2012).
- Tao Y , WangF , ShenXet al. BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer. J. Clin. Endocrinol. Metabol.106(11), 3228–3238 (2021).
- Das PM , SingalR. DNA methylation and cancer. J. Clin. Oncol.22(22), 4632–4642 (2004).
- Klutstein M , NejmanD , GreenfieldR , CedarH. DNA methylation in cancer and aging. Cancer Res.76(12), 3446–3450 (2016).
- Jensen K , PatelA , HoperiaV , LarinA , BauerA , VaskoV. Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer. Exp. Ther. Med.1(3), 457–462 (2010).
- Wang P , PeiR , LuZ , RaoX , LiuB. Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma. JCMA76(3), 135–139 (2013).
- Tomczak K , CzerwińskaP , WiznerowiczM. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. (Poznan, Poland)19(1a), A68–A77 (2015).
- Beltrami CM , DosReis MB , Barros-FilhoMCet al. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas. Clin. Epigenetics9, 45 (2017).
- Bisarro Dos Reis M , Barros-FilhoMC , MarchiFAet al. Prognostic classifier based on genome-wide DNA methylation profiling in well-differentiated thyroid tumors. J. Clin. Endocrinol. Metabol.102(11), 4089–4099 (2017).
- Shiny Methylation Analysis Resource Tool (SMART) . www.bioinfo-zs.com/smartapp/
- UCSC Genomics Institute.Genome Browser . http://genome.ucsc.edu/
- MethPrimer 2.0 . www.urogene.org/methprimer2/
- Pellegriti G , FrascaF , RegalbutoC , SquatritoS , VigneriR. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J. Cancer Epidemiol.2013, 965212 (2013).
- Kitahara CM , SosaJA. The changing incidence of thyroid cancer. Nat. Rev. Endocrinol.12(11), 646–653 (2016).
- Mazzaferri EL , JhiangSM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med.97(5), 418–428 (1994).
- Sakorafas GH , SampanisD , SafioleasM. Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg. Oncol.19(2), e57–e70 (2010).
- Wu B-K , MeiS-C , ChenEH , ZhengY , PanD. YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis. Nat. Genet.54(8), 1202–1213 (2022).
- Zhu X , XueC , KangXet al. DNMT3B-mediated FAM111B methylation promotes papillary thyroid tumor glycolysis, growth and metastasis. Int. J. Biol. Sci.18(11), 4372–4387 (2022).
- Ahn HR , BaekGO , YoonMGet al. Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma. J. Exp. Clin. Cancer Res.41(1), 158 (2022).
- Sun D , GanX , LiuLet al. DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334. Cell Death Dis.13(5), 446 (2022).
- Puxeddu E , DuranteC , AveniaN , FilettiS , RussoD. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol. Metab.19(4), 138–145 (2008).
- Dvorakova M , NenutilR , BouchalP. Transgelins, cytoskeletal proteins implicated in different aspects of cancer development. Expert Rev. Proteomics11(2), 149–165 (2014).
- Wei X , LouH , ZhouDet al. TAGLN mediated stiffness-regulated ovarian cancer progression via RhoA/ROCK pathway. J. Exp. Clin. Cancer Res.40(1), 292 (2021).
- Chen Z , HeS , ZhanYet al. TGF-β-induced transgelin promotes bladder cancer metastasis by regulating epithelial-mesenchymal transition and invadopodia formation. EBioMedicine47, 208–220 (2019).
- Lin X , GuoL , LinX , WangY , ZhangG. Expression and prognosis analysis of mitochondrial ribosomal protein family in breast cancer. Sci. Rep.12(1), 10658 (2022).
- Xiang Z , ZhongC , ChangAet al. Immune-related key gene CLDN10 correlates with lymph node metastasis but predicts favorable prognosis in papillary thyroid carcinoma. Aging12(3), 2825–2839 (2020).
- Yang W , ZhangK , ZhangZet al. Claudin-10 overexpression suppresses human clear cell renal cell carcinoma growth and metastasis by regulating ATP5O and causing mitochondrial dysfunction. Int. J. Biol. Sci.18(6), 2329–2344 (2022).
- Huang J , TengL , LiuTet al. Identification of a novel serine/threonine kinase that inhibits TNF-induced NF-κB activation and p53-induced transcription. Biochem. Biophys. Res. Comm.309(4), 774–778 (2003).
- Paschen W , BlackstoneCD , HuganirRL , RossCA. Human GluR6 kainate receptor (GRIK2): molecular cloning, expression, polymorphism, and chromosomal assignment. Genomics20(3), 435–440 (1994).
- Barbon A , ValliniI , BarlatiS. Genomic organization of the human GRIK2 gene and evidence for multiple splicing variants. Gene274(1–2), 187–197 (2001).
- Zhawar VK , KaurG , DerielJK , KaurGP , KandpalRP , AthwalRS. Novel spliced variants of ionotropic glutamate receptor GluR6 in normal human fibroblast and brain cells are transcribed by tissue specific promoters. Gene459(1–2), 1–10 (2010).
- Wu CS , LuYJ , LiHPet al. Glutamate receptor, ionotropic, kainate 2 silencing by DNA hypermethylation possesses tumor suppressor function in gastric cancer. Int. J. Cancer126(11), 2542–2552 (2010).
- Zhawar VK , KandpalRP , AthwalRS. Isoforms of Ionotropic Glutamate Receptor GRIK2 Induce Senescence of Carcinoma Cells. Cancer Genom. Proteom.16(1), 59–64 (2019).
- Zhawar VK , KandpalRP , AthwalRS. Alternative promoters of GRIK2 (GluR6) gene in human carcinoma cell lines are regulated by differential methylation of CpG dinucleotides. Genes (Basel)13(3), 493 (2022).
- Wade PA , GegonneA , JonesPL , BallestarE , AubryF , WolffeAP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet.23(1), 62–66 (1999).